Dr. Carneiro, PhD
Claim this profileLund University Hospital
Studies Solid Tumors
1 reported clinical trial
2 drugs studied
Area of expertise
1Solid Tumors
Stage IV
PD-L1 positive
PD-L1 negative
Clinical Trials Carneiro, PhD is currently running
More about Carneiro, PhD
Clinical Trial Related5 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical TrialTreatments Carneiro, PhD has experience with
- BI-1206
- Pembrolizumab
Breakdown of trials Carneiro, PhD has run
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Carneiro, PhD specialize in?
Carneiro, PhD focuses on Solid Tumors and other conditions. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are PD-L1 positive.
Is Carneiro, PhD currently recruiting for clinical trials?
Yes, Carneiro, PhD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Carneiro, PhD has studied deeply?
Yes, Carneiro, PhD has studied treatments such as BI-1206, Pembrolizumab.
What is the best way to schedule an appointment with Carneiro, PhD?
Apply for one of the trials that Carneiro, PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.